Quantum Biopharma Stock Performance
| QNTM Stock | 4.01 0.07 1.72% |
On a scale of 0 to 100, Quantum BioPharma holds a performance score of 2. The company holds a Beta of 0.32, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Quantum BioPharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Quantum BioPharma is expected to be smaller as well. Please check Quantum BioPharma's value at risk, and the relationship between the jensen alpha and skewness , to make a quick decision on whether Quantum BioPharma's historical price patterns will revert.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Quantum BioPharma are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very conflicting basic indicators, Quantum BioPharma displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.72) | Five Day Return (5.87) | Year To Date Return (1.72) | Ten Year Return (99.64) | All Time Return (99.64) |
Last Split Factor 1:65 | Last Split Date 2024-08-15 |
1 | Quantum Biopharmas Financial Growth and Stability - TipRanks | 11/12/2024 |
2 | Quantum BioPharma Makes Bold 1M Bitcoin Investment, Embraces Crypto for Future Transactions - StockTitan | 12/20/2024 |
| Begin Period Cash Flow | 17 M |
Quantum |
Quantum BioPharma Relative Risk vs. Return Landscape
If you would invest 411.00 in Quantum BioPharma on October 8, 2024 and sell it today you would lose (10.00) from holding Quantum BioPharma or give up 2.43% of portfolio value over 90 days. Quantum BioPharma is currently generating 0.2692% in daily expected returns and assumes 8.0192% risk (volatility on return distribution) over the 90 days horizon. In different words, 71% of stocks are less volatile than Quantum, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Quantum BioPharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Quantum BioPharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Quantum BioPharma, and traders can use it to determine the average amount a Quantum BioPharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0336
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | QNTM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.02 actual daily | 71 71% of assets are less volatile |
Expected Return
| 0.27 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Quantum BioPharma is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Quantum BioPharma by adding it to a well-diversified portfolio.
Quantum BioPharma Fundamentals Growth
Quantum Stock prices reflect investors' perceptions of the future prospects and financial health of Quantum BioPharma, and Quantum BioPharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Quantum Stock performance.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.36 | ||||
| Current Valuation | 3.47 M | ||||
| Shares Outstanding | 1.55 M | ||||
| Price To Book | 0.55 X | ||||
| Price To Sales | 91.86 X | ||||
| EBITDA | (10.06 M) | ||||
| Net Income | (17.9 M) | ||||
| Total Debt | 300.55 K | ||||
| Book Value Per Share | 15.02 X | ||||
| Cash Flow From Operations | (10.83 M) | ||||
| Earnings Per Share | (13.00) X | ||||
| Total Asset | 17.47 M | ||||
| Retained Earnings | (157.91 M) | ||||
About Quantum BioPharma Performance
By examining Quantum BioPharma's fundamental ratios, stakeholders can obtain critical insights into Quantum BioPharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Quantum BioPharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Quantum BioPharma is entity of United States. It is traded as Stock on NASDAQ exchange.Things to note about Quantum BioPharma performance evaluation
Checking the ongoing alerts about Quantum BioPharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Quantum BioPharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Quantum BioPharma had very high historical volatility over the last 90 days | |
| Quantum BioPharma has a very high chance of going through financial distress in the upcoming years | |
| Quantum BioPharma was previously known as HUGE Old and was traded on NASDAQ Exchange under the symbol HUGE. | |
| Net Loss for the year was (17.9 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Quantum BioPharma generates negative cash flow from operations | |
| Quantum BioPharma has a very weak financial position based on the latest SEC disclosures | |
| About 14.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Quantum BioPharma Makes Bold 1M Bitcoin Investment, Embraces Crypto for Future Transactions - StockTitan |
- Analyzing Quantum BioPharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Quantum BioPharma's stock is overvalued or undervalued compared to its peers.
- Examining Quantum BioPharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Quantum BioPharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Quantum BioPharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Quantum BioPharma's stock. These opinions can provide insight into Quantum BioPharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Quantum BioPharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Quantum Stock, please use our How to Invest in Quantum BioPharma guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Quantum BioPharma. If investors know Quantum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Quantum BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Quantum BioPharma is measured differently than its book value, which is the value of Quantum that is recorded on the company's balance sheet. Investors also form their own opinion of Quantum BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Quantum BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Quantum BioPharma's market value can be influenced by many factors that don't directly affect Quantum BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Quantum BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Quantum BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Quantum BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.